|
業務類別
|
-- |
|
業務概覽
|
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis). |
| 公司地址
| 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324 |
| 電話號碼
| +81 332816611 |
| 傳真號碼
| +81 332812828 |
| 公司網頁
| https://www.chugai-pharm.co.jp |
| 員工數量
| 7778 |
| Dr. Osamu Okuda |
President, Director and Chief Executive Officer |
-- |
25/03/2026 |
| Mr. Hitoshi Iikura |
Director, Executive Vice President and Head of Corporate Planning Dept |
-- |
25/03/2026 |
| Mr. Iwaaki Taniguchi |
Director, Executive Vice President and Chief Financial Officer |
-- |
25/03/2026 |
|
|
| Mr. Fumio Tateishi |
Independent Director |
25/03/2026 |
| Ms. Mariko Y. Momoi |
Independent Director |
25/03/2026 |
| Dr. Osamu Okuda |
President, Director and Chief Executive Officer |
25/03/2026 |
| Mr. Hitoshi Iikura |
Director, Executive Vice President and Head of Corporate Planning Dept |
25/03/2026 |
| Ms. Kinuko Mitani |
Independent Director |
25/03/2026 |
| Mr. Boris L. Zaitra |
Director |
25/03/2026 |
| Ms. Teresa A. Graham |
Director |
25/03/2026 |
| Mr. Hideo Teramoto |
Independent Director |
25/03/2026 |
| Mr. Iwaaki Taniguchi |
Director, Executive Vice President and Chief Financial Officer |
25/03/2026 |
| Mr. Thomas Schinecker |
Director |
25/03/2026 |
|
|
|
|
